Diabetic retinopathy is a major cause of blindness, particularly among working-age adults. The degree of retinopathy is highly correlated with
Pregnancy can impair blood glucose control and thus worsen retinopathy.
Proliferative retinopathy develops after nonproliferative retinopathy and is more severe; it may lead to vitreous hemorrhage and traction retinal detachment. Proliferative retinopathy is characterized by abnormal new vessel formation (neovascularization), which occurs on the inner (vitreous) surface of the retina and may extend into the vitreous cavity and cause vitreous hemorrhage. Neovascularization is often accompanied by preretinal fibrous tissue, which, along with the vitreous, can contract, resulting in traction retinal detachment. Neovascularization may also occur in the anterior segment of the eye on the iris; neovascular membrane growth in the anterior chamber angle of the eye at the peripheral margin of the iris can occur, and this growth leads to neovascular glaucoma. Vision loss with proliferative retinopathy may be severe.
Clinically significant macular edema can occur with nonproliferative or proliferative retinopathy and is the most common cause of vision loss due to diabetic retinopathy.
Vision symptoms are caused by macular edema or macular ischemia. However, patients may not have vision loss even with advanced retinopathy. The first signs of nonproliferative retinopathy are
Hard exudates are discrete, yellow particles within the retina. When present, they suggest chronic edema. Cotton-wool spots are areas of microinfarction of the retinal nerve fiber layer that lead to retinal opacification; they are fuzzy-edged and white and obscure underlying vessels.
Signs in later stages are
Symptoms may include blurred vision, floaters (black spots) or flashing lights in the field of vision, and sudden, severe, painless vision loss. These symptoms are typically caused by vitreous hemorrhage or traction retinal detachment.
Proliferative retinopathy, unlike nonproliferative retinopathy, causes formation of fine preretinal vessel neovascularization visible on the optic nerve or retinal surface. Macular edema or retinal hemorrhage may be visible on funduscopy.
Diagnosis is by funduscopy. Color fundus photography helps grade the level of retinopathy. Fluorescein angiography is used to determine the extent of retinopathy, to develop a treatment plan, and to monitor the results of treatment. Optical coherence tomography is also useful to assess severity of macular edema and treatment response.
Control of blood glucose and blood pressure (BP)
For macular edema, intraocular injection of antivascular endothelial growth factor (anti-VEGF) drugs, intraocular corticosteroid implants, focal laser, and/or vitrectomy
For high-risk or complicated proliferative retinopathy, anti-VEGF drugs, panretinal laser photocoagulation and sometimes vitrectomy
Control of blood glucose and BP are critical; intensive control of blood glucose slows progression of retinopathy. Clinically significant diabetic macular edema is treated with intraocular injection of anti-VEGF drugs (eg, ranibizumab, bevacizumab, aflibercept) and/or with focal laser photocoagulation (1 Treatment references Manifestations of diabetic retinopathy include microaneurysms, intraretinal hemorrhage, exudates, macular edema, macular ischemia, neovascularization, vitreous hemorrhage, and traction retinal... read more ). The intraocular dexamethasone implant and intravitreal triamcinolone can treat eyes with persistent macular edema. In certain countries, an intraocular fluocinolone implant is available for patients with chronic diabetic macular edema. Vitrectomy can help in recalcitrant diabetic macular edema. In select cases of severe nonproliferative retinopathy, panretinal laser photocoagulation may be used; however, usually panretinal laser photocoagulation can be delayed until proliferative retinopathy develops.
Proliferative diabetic retinopathy with high-risk characteristics of vitreous hemorrhage, extensive preretinal neovascularization, or anterior segment neovascularization/neovascular glaucoma should be treated with panretinal laser photocoagulation. Recent studies have also supported the use of intravitreal anti-VEGF drugs in the treatment of proliferative diabetic retinopathy (2 Treatment references Manifestations of diabetic retinopathy include microaneurysms, intraretinal hemorrhage, exudates, macular edema, macular ischemia, neovascularization, vitreous hemorrhage, and traction retinal... read more ). These treatments significantly reduce the risk of severe vision loss.
Vitrectomy can help preserve and often restore lost vision in patients with any of the following:
The Diabetic Retinopathy Clinical Research Network: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med372(13):1193-1203, 2015. doi:10.1056/NEJMoa1414264.
Beaulieu WT, Bressler NM, Melia M, et al: Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: Patient-centered outcomes from a randomized clinical trial. Am J Ophthalmol 170:206-213, 2016. doi: 10.1016/j.ajo.2016.08.008.
Features of diabetic retinopathy can include microaneurysms, intraretinal hemorrhage, exudates, cotton-wool spots, macular edema, macular ischemia, neovascularization, vitreous hemorrhage, and traction retinal detachment.
Symptoms may not develop until damage is advanced.
Test patients who have diabetic retinopathy with color fundus photography, fluorescein angiography, and optical coherence tomography.
Screen all diabetic patients with an annual dilated ophthalmologic examination.
Treat patients with macular edema with intraocular anti-VEGF drugs (eg, ranibizumab, aflibercept, bevacizumab), intraocular corticosteroid implants, focal laser photocoagulation, and/or vitrectomy.
Treat patients with high-risk or complicated proliferative retinopathy with panretinal laser photocoagulation, anti-VEGF drugs, and/or sometimes vitrectomy.